VIVUS (VVUS) Earning Somewhat Positive Media Coverage, Report Shows

Media coverage about VIVUS (NASDAQ:VVUS) has trended somewhat positive on Tuesday, Accern Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. VIVUS earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.1168635440846 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the news headlines that may have effected Accern’s scoring:

VVUS has been the subject of a number of research reports. ValuEngine cut shares of VIVUS from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Zacks Investment Research cut shares of VIVUS from a “buy” rating to a “hold” rating in a research note on Saturday.

VIVUS (VVUS) traded down $0.02 during midday trading on Tuesday, hitting $0.51. 416,400 shares of the stock were exchanged, compared to its average volume of 477,500. The company has a current ratio of 7.47, a quick ratio of 7.09 and a debt-to-equity ratio of 643.86. The firm has a market cap of $54.93, a PE ratio of 1.55 and a beta of 0.80. VIVUS has a one year low of $0.48 and a one year high of $1.38.

VIVUS (NASDAQ:VVUS) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.07. VIVUS had a net margin of 26.71% and a return on equity of 344.23%. The business had revenue of $15.19 million for the quarter, compared to analyst estimates of $16.00 million. During the same period last year, the firm earned ($0.09) earnings per share. VIVUS’s revenue for the quarter was up 13.8% compared to the same quarter last year. equities analysts anticipate that VIVUS will post -0.32 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first reported by Markets Daily and is owned by of Markets Daily. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at

VIVUS Company Profile

VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

Insider Buying and Selling by Quarter for VIVUS (NASDAQ:VVUS)

Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply